This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Friday's Asia ADR Recap: Perfect World

Stocks in India closed on a sour note on Friday after government data showed that inflation jumped to a seven-year high due to runaway energy prices and soaring food prices. Annual inflation, which is measured by India's Wholesale Price Index, rose 8.75% for the week ending on May 31, vs. 8.24% in the previous week. Analysts in the Far East now fear that another rate hike is in the cards when the Indian Central Bank meets next month.

"We expect the Reserve Bank to raise the repurchase rate by a further 25 basis points in the next policy meeting,'' said Tushar Poddar, an economist at Goldman Sachs Group in Mumbai. "We also expect a further 50 basis points increase in the cash reserve ratio in the remaining of 2008."

The Bombay Stock Exchange's Sensex Index lost 60.58 points, or 0.40%, to 15,189.62. Here's a look at how some India-based American depositary shares traded in the U.S. on Friday.

India's second-largest pharmaceutical manufacturer, Dr. Reddy's (RDY), announced the launch of the Dr. Reddy's Laboratories Generics Company Intelligence Report. The new reports will help investors understand the complex issues surrounding Dr. Reddy's in the generic drug market. Some of the topics covered in the reports will be quarterly and annual financial results, information on the company's products and drug approvals, M&A activity, strategic alliances and litigation. American depositary shares of Dr. Reddy's, which trade on the NYSE, rose 1.2% to $16.68.

Elsewhere in the Indian drug sector, U.S.-based pharmaceutical giant Pfizer (PFE) is rumored to be considering a hostile takeover offer for Ranbaxy Laboratories, India's largest drug maker, according to the Business Standard newspaper. Pfizer is reportedly considering an offer to buy 65% of Ranbaxy stock that isn't held by the Singh family, which would counter Japanese drugmaker Daiichi Sankyo's agreed takeover price of $4.6 billion for a 50.1% stake. Shares of Pfizer moved up 1.4% to $17.99, and shares of Ranbaxy jumped 4.3% in India.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,113.54 +61.81 0.36%
S&P 500 1,983.53 +9.90 0.50%
NASDAQ 4,456.0160 +31.3120 0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs